Therefore, any compound that targets the hepcidin-FPN1 axis exerts both systemic and local effects and needs to be thoroughly tested in preclinical cancer models and clinical cancer trials to carefully balance the benefit-risk ratio of such products before approval for clinical use. Here, SLC40A1 is linked to cancer.